Search company, investor...
Momenta Pharmaceuticals company logo

Momenta Pharmaceuticals

momentapharma.com

Founded Year

2001

Stage

Acq - P2P | Acquired

Total Raised

$45.68M

Valuation

$0000 

About Momenta Pharmaceuticals

Momenta Pharmaceuticals (NASDAQ: MNTA) is a biotechnology company with a validated scientific platform focused on discovering and developing biologic therapeutics to treat rare immune-mediated diseases and advancing its late stage biosimilars.On August 19th, 2020, Momenta Pharmaceuticals was acquired by Johnson & Johnson.5B.

Headquarters Location

301 Binney Street

Cambridge, Massachusetts, 02142,

United States

617-491-9700

Missing: Momenta Pharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Momenta Pharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Momenta Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Momenta Pharmaceuticals is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Momenta Pharmaceuticals Patents

Momenta Pharmaceuticals has filed 1 patent.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Immunology
  • Immune system
patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/1/2019

6/7/2022

Clusters of differentiation, Cytokines, Acetylcholinesterase inhibitors, Immune system, Immunology

Grant

Application Date

11/1/2019

Grant Date

6/7/2022

Title

Related Topics

Clusters of differentiation, Cytokines, Acetylcholinesterase inhibitors, Immune system, Immunology

Status

Grant

Latest Momenta Pharmaceuticals News

Global TNF Alpha Inhibitors Market Report 2022-2026 & 2031 Featuring Major Players - AbbVie, Amgen, J&J, UCB, Novartis, Pfizer, Merck & Co, Janssen Biotech, Ablynx, and Momenta Pharmaceuticals

Aug 4, 2022

The global TNF Alpha Inhibitors market is expected to grow from $38.56 billion in 2021 to $40.73 billion in 2022 at a compound annual growth rate (CAGR) of 5.6%. The market is expected to reach $43.83 billion in 2026 at a CAGR of 1.9%. Major players in the TNF alpha inhibitors market are AbbVie Inc., Amgen Inc., Johnson & Johnson Services Inc., UCB S.A, Novartis International AG, Pfizer Inc., Merck & co. Inc., Janssen Biotech, Ablynx, and Momenta Pharmaceuticals. The TNF alpha inhibitors market consists of sales of tumor necrosis factor-alpha (TNF-a) inhibitors by entities that manufacture TNF alpha inhibitors. TNF alpha inhibitors are a group of medicines that conquer the body's natural response to TNF, a protein produced by white blood cells, involved in early inflammatory events. These are important treatments in the number of inflammatory conditions including spondylarthritis, psoriasis, rheumatoid arthritis (RA), and inflammatory bowel disease (IBD). The main types of drugs in TNF alpha inhibitors are remicade (infliximab), enbrel (etanercept), humira (adalimumab), cimzia (certolizumab pegol) and simponi (golimumab). REMICADE is a prescription drug for persons with slightly to severely active Crohn's disease who haven't had success with other treatments. The different routes of administration include oral, subcutaneous, intravenous, others and involves various types of diseases such as inflammatory bowel disease, psoriatic arthritis, ulcerative colitis (uc), rheumatoid arthritis, ankylosing spondylitis, others. The growing prevalence of inflammatory diseases such as inflammatory bowel disease and psoriasis is a key factor driving the growth of the TNF alpha inhibitors market. Tumor necrosis factor-alpha (TNF alpha) inhibitors are commonly used in gastroenterology, dermatology and rheumatology for the treatment of various immune-mediated inflammatory diseases. Globally, the prevalence of inflammatory bowel disease (IBD) is about 0.5-24.5 cases for ulcerative colitis per 100,000 person-years and 0.1-16 cases for Crohn's disease per 100,000 person-years, and overall, IBD prevalence is 396 cases per 100,000 people each year. Thus, the increasing number of cases of inflammatory diseases increases the demand for TNF alpha inhibitors contributing to the growth of the market. The adverse side effects of TNF alpha inhibitors on patients are expected to limit the growth of the TNF alpha inhibitors market. The multiple adverse effects of TNF alpha inhibition identified by clinical trials and post-marketing surveillance include injection site reactions, neutropenia, infusion reactions, and infections. According to the U.S. Food and Drug Administration (FDA), TNA alpha inhibitors can cause serious infections in people with weaker immune systems or low resistance levels. The infections can be bacterial, mycobacterial, fungal, and viral leading to various diseases such as tuberculosis, histoplasmosis, candidiasis, blastomycosis, and hepatitis B. These side effects force patients to prefer alternatives such as non-TNF biologics, which hampers the growth of the market. The countries covered in the TNF alpha inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. Key Topics Covered:

Momenta Pharmaceuticals Frequently Asked Questions (FAQ)

  • When was Momenta Pharmaceuticals founded?

    Momenta Pharmaceuticals was founded in 2001.

  • Where is Momenta Pharmaceuticals's headquarters?

    Momenta Pharmaceuticals's headquarters is located at 301 Binney Street, Cambridge.

  • What is Momenta Pharmaceuticals's latest funding round?

    Momenta Pharmaceuticals's latest funding round is Acq - P2P.

  • How much did Momenta Pharmaceuticals raise?

    Momenta Pharmaceuticals raised a total of $45.68M.

  • Who are the investors of Momenta Pharmaceuticals?

    Investors of Momenta Pharmaceuticals include Johnson & Johnson, Polaris Partners, MVM Partners, Cardinal Partners, Atlas Venture and 3 more.

  • Who are Momenta Pharmaceuticals's competitors?

    Competitors of Momenta Pharmaceuticals include Phico Therapeutics, OcuNexus Therapeutics, Lead Pharma, InflaRx, Pier Pharmaceuticals and 12 more.

Compare Momenta Pharmaceuticals to Competitors

A
Aero Pharmaceuticals

Aero Pharmaceuticals, Inc markets lines of dermatological products under Baker Cummins Dermatologicals. Baker Cummins Dermatologicals markets a line of scalp and skin care products that can be used to treat dry skin and scalp conditions commonly seen.

L
Labormed Pharma

LaborMed Pharma, aims to offer modern and accessible treatments for cardiovascular diseases, those affecting the central nervous system, the metabolism a.s.o., medicines produced in a state-of-the-art factory in Bucharest.

O
OcuNexus Therapeutics

OcuNexus Therapeutics is a development stage biopharmaceutical company that develops treatments for front- and back-of-the-eye diseases and disorders.

A
ALEXIS Biochemicals

ALEXIS Biochemicals is an internationally recognized brand acknowldeged as engaged in producing and commercializing high quality reagents in key research areas and an established source for a panel of products to scientific experts in the field.

Phico Therapeutics Logo
Phico Therapeutics

Phico Therapeutics is developing SASPject PT3.8, an antibacterial therapy for the systemic treatment of patients with serious Pseudomonas aeruginosa (P. aeruginosa) infections, which have a high mortality rate.

N
NovaDigm Therapeutics

NovaDigm Therapeutics is developing vaccines to protect patients from fungal and bacterial infections, which can be life-threatening and drug resistant. The company's lead product candidate, NDV-3, is a recombinant glycoprotein vaccine containing a candidal surface antigen, agglutinin-like sequence 3 protein or Als3. Results from a Phase 1 clinical trial demonstrated that a single dose of the NDV-3 vaccine was safe, well-tolerated and induced strong antibody and T-cell immune responses in healthy adults.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.